have introduced a novel copper chelator, JYFY‐001, which demonstrates efficacy in inhibiting tumor cell proliferation, inducing apoptosis, and enhancing the antitumor effects of programmed cell death protein 1 (PD‐1) inhibitors, while also exhibiting a favorable safety profile. Here, PDCD1 is linked to neoplasm.